Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIC pediatric alemtuzumab exposure study before allogeneic stem cell transplantation
NL-OMON55607Completed
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of alemtuzumab in Immunogenetic disorder, severe combined immunodeficiency (SCID), haemophagocytic lymphohistiocytosis (HLH) and 3 more, sponsored by Leiden University Medical Center. Primary endpoint: Alemtuzumab concentration-time profile. Started Mar 2020; status: completed.
02
Drugs
alemtuzumab
03
Conditions
Immunogenetic disordersevere combined immunodeficiency (SCID)haemophagocytic lymphohistiocytosis (HLH)chronic granulomatous disease (CGD)beta thalassemia major
Beyond the preview
Go deeper on NL-OMON55607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55607.